Home / Knowledge Centre /
Article

Antibody-Drug Conjugates: Carbon-14 Labeling Requirements

The next blockbuster drug revenue streams are likely to come from a class of targeted therapies geared towards the treatment and management of chronic human disease states, especially cancer, and involve the use of antibody-drug conjugates (ADCs).
This article, published in Drug Development and Delivery magazine, May 2013, looks at carbon-14 labelling requirements for these types of drugs and their future development.

View Resource

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies